Roche Diagnostics Licenses Melting Curve Analysis Technique to Agilent Technologies
News Aug 04, 2008
Roche Diagnostics and Agilent Technologies announced that they have entered into a non-exclusive licensing agreement for use of Roche’s melting curve analysis technology.
Under the terms of the agreement, Agilent will obtain from Roche a non-exclusive license to use, develop and sell products based on melting curve analysis. Financial terms of the agreement were not disclosed.
“The licensing of the melting curve analysis technique to Agilent is one more contribution of Roche to further boost development of this technology in the life science field,” states Manfred Baier, Head of Roche Applied Science, a business area of Roche Diagnostics.
“We are pleased to be working with Roche and look forward to offering this technology as part of our growing life sciences portfolio,” said Bill Molnar, vice president and general manager of Agilent’s Bioreagents Division.
The melting curve analysis is a technique for analysis of PCR products. After PCR, the resulting PCR product is slowly heated. Each double-stranded DNA has its own specific melting temperature, which is defined as the temperature at which 50 percent of the DNA becomes single stranded.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.